ESMO: Seagen and Genmab's Tivdak keeps cervical cancer patients alive longer

On the verge of a $43 billion powerhouse merger with Pfizer, Seagen has two Presidential Symposium presentations at the European Society of Medical Oncology (ESMO) Congress in Madrid, further evidence of the influence antibody-drug conjugates are wielding in the cancer arena.